Environmentally classified pharmaceuticals

Two substances may have the same risk values but different PBT values, but the risk assessment can also be different even if the PBT values are the same. When assessing a medication's environmental impact, consideration should be given to both environmental risk and environmental hazard since bioaccumulation and persistence are not included in the risk assessment.

The Swedish Association of the Pharmaceutical Industry conducted the environmental risk assessment, beginning in 2005.

How to read the table

Last updated: 2010-01-11

« New search


M Musculo-skeletal system

 Substance  Risk  PBT  P  B  T  Volume in DDD  ATC
Anti-inflammatory and antirheumatic products M01
ibuprofen isigni-
ficant
2 0 0 2 12 684 839 
C, E 751 675 
M01A E01
M01A E51
M02A A13
C01E B16
ketorolac isigni-
ficant
4 3 0 1 24 055  M01A B15
diclofenac isigni-
ficant
4
N.B.
3 0
N.B.
1 8 323 144 
C, E 10 648 975 
M01A B05
M01A B55
M02A A15
S01B C03
naproxen low 4 3 0 1 2 970 600  M01A E02
nabumetone cannot be excl  -  -  -  - 430 516  M01A X01
meloxicam isigni-
ficant
4 3 0 1 92 525  M01A C06
etoricoxib insigni-
ficant
5 3 0 2 1 389 444  M01A H05
glucosamine low 1 0 0 1 4 022 256  M01A X05
indometacin cannot be excl 5
N.B.
3 0 2
N.B.
98 728  M01A B01
ketoprofen cannot be excl 7
N.B.
3
N.B.
3 1 1 941 123 
U 8 827 510 
M01A E03
M02A A10
sodium
aurothiomalate
cannot be excl  -  -  -  - 4 750  M01C B01
sulindac cannot be excl 4 180  M01A B02
tenoxicam   4 3 0 1 102 080  M01A C02
Topical products for joint and muscular pain M02
ibuprofen isigni-
ficant
2 0 0 2 12 684 839 
C, E 751 675
M01A E01
M01A E51
M02A A13
C01E B16
diclofenac isigni-
ficant
4
N.B.
3 0
N.B.
1 8 323 144 
C, E 10 648 975 
M01A B05
M01A B55
M02A A15
S01B C03
dietylamino-
salicylat
cannot be excl 1
N.B.
0 0 1
N.B.

E 1 069 900 
M02 AC
ketoprofen cannot be excl 7
N.B.
3
N.B.
3 1 1 941 123 
E 8 827 510
M01A E03
M02A A10
Muscle relaxant M04
atracurium cannot be excl 2
N.B.
0 0 2
N.B.
M03A C04
cisatrakurium cannot be excl 2
N.B.
0 0 2
N.B.
M03A C11
baclofen cannot be excl 3
N.B.
3 0 0
N.B.
336 990  M03B X01
mivacurium
chloride
cannot be excl 3
N.B.
3 0 0
N.B.
M03A C10
chlorzoxazone cannot be excl 234 540  M03B B03
suxamethonium cannot be excl M03A B01
Antigout preparations M04
allopurinol moderate 6 3 0 3 1 477 226 
M04A A01
V07AB
probenecid cannot be excl 101 615  M04A B01
Drugs for treatment of bone diseases M05
pamidronic acid insigni-
ficant
4
N.B.
3
N.B.
0 1
N.B.
2 504  M05B A03
zoledronic acid insigni-
ficant
5
N.B.
3 0 2
N.B.
2 141  M05B A08
alendronic acid insigni-
ficant
6 3 0 3 3 373 742 
C 210 252 
M05B A04
M05B B03
ibandronic acid insigni-
ficant
2 0 0 2 575 388  M05B A06
clodronic acid insigni-
ficant
4 3 0 1 14 320  M05B A02
etidronic acid insigni-
ficant
5 3 0 2 4 382 
K 10 458 
M05B A01
M05B B01
risedronic acid insigni-
ficant
6
N.B.
3
N.B.
0 3 1 213 464 
C 15 708 
M05B A07
M05B B02
M05B B04